

Chiara Napoletano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214907/publications.pdf>

Version: 2024-02-01

51
papers

1,556
citations

236833

25
h-index

315616

38
g-index

51
all docs

51
docs citations

51
times ranked

2703
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1027-1037.	3.2	10
2	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2 ⁺ metastatic breast cancer: Relief from immunosuppression is associated with clinical response. <i>EBioMedicine</i> , 2022, 79, 104010.	2.7	22
3	Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6312.	1.8	6
4	Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. <i>Scientific Reports</i> , 2021, 11, 2557.	1.6	16
5	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	1.1	28
6	Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. <i>Frontiers in Oncology</i> , 2021, 11, 755433.	1.3	15
7	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL). <i>Cancers</i> , 2020, 12, 2841.	1.7	10
8	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2620.	1.7	21
9	Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma. <i>Journal of Personalized Medicine</i> , 2020, 10, 112.	1.1	20
10	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208.	1.1	23
11	Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. <i>Journal of Clinical Medicine</i> , 2019, 8, 380.	1.0	25
12	Neoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2019, 7, S305-S305.	0.7	2
13	TK Inhibitor Pazopanib Primes DCs by Downregulation of the β -Catenin Pathway. <i>Cancer Immunology Research</i> , 2018, 6, 711-722.	1.6	47
14	Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2481.	2.2	23
15	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2018, 150, 151-157.	0.6	21
16	Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1179.	2.2	21
17	TGF- β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures. <i>PLoS ONE</i> , 2017, 12, e0183932.	1.1	33
18	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> , 2017, 8, 8890-8899.	0.8	48

#	ARTICLE	IF	CITATIONS
19	Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.. Journal of Clinical Oncology, 2017, 35, e14506-e14506.	0.8	4
20	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. Oncotarget, 2017, 8, 99336-99346.	0.8	76
21	Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 2016, 48, 1369-1378.	1.4	28
22	Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. Anticancer Research, 2016, 36, 5109-5116.	0.5	11
23	The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions. PLoS ONE, 2015, 10, e0132617.	1.1	35
24	Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS ONE, 2015, 10, e0142124.	1.1	27
25	MGL Receptor and Immunity: When the Ligand Can Make the Difference. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	49
26	Profiles of Cancer Stem Cell Subpopulations in Cholangiocarcinomas. American Journal of Pathology, 2015, 185, 1724-1739.	1.9	87
27	Optimization of the isolation and expansion method of human mediastinal adipose tissue derived mesenchymal stem cells with virally inactivated GMP-grade platelet lysate. Cytotechnology, 2015, 67, 165-174.	0.7	30
28	Transplantation of human fetal biliary tree stem/progenitor cells into two patients with advanced liver cirrhosis. BMC Gastroenterology, 2014, 14, 204.	0.8	49
29	Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing. Cancer Immunology Research, 2014, 2, 177-186.	1.6	23
30	The Fas/Fas ligand apoptosis pathway underlies immunomodulatory properties of human biliary tree stem/progenitor cells. Journal of Hepatology, 2014, 61, 1097-1105.	1.8	37
31	Evidence for multipotent endodermal stem/progenitor cell populations in human gallbladder. Journal of Hepatology, 2014, 60, 1194-1202.	1.8	62
32	Suitability of Human Tenon's Fibroblasts as Feeder Cells for Culturing Human Limbal Epithelial Stem Cells. Stem Cell Reviews and Reports, 2013, 9, 847-857.	5.6	22
33	A standardized laboratory and surgical method for in vitro culture isolation and expansion of primary human Tenon's fibroblasts. Cell and Tissue Banking, 2013, 14, 277-287.	0.5	24
34	Interaction between treg cells and angiogenesis: A dark double track. International Journal of Cancer, 2013, 132, 2469-2469.	2.3	6
35	Seasonal modulation of the C-type lectin MGL on human DCs. Open Journal of Immunology, 2013, 03, 218-220.	0.5	2
36	Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens. International Journal of Clinical Oncology, 2012, 17, 385-389.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Targeting of macrophage galactose-type C lectin (MGL) induces DC signaling and activation. <i>European Journal of Immunology</i> , 2012, 42, 936-945.	1.6	84
38	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 35-46.	2.0	27
39	Immune Effects of Trastuzumab. <i>Journal of Cancer</i> , 2011, 2, 317-323.	1.2	35
40	HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2011, 89, 1231-1240.	1.7	12
41	Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-16.	3.3	38
42	Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. <i>Investigational New Drugs</i> , 2010, 28, 887-894.	1.2	44
43	Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2748-2759.	1.6	61
44	Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy. <i>Journal of Clinical Oncology</i> , 2010, 28, e369-e370.	0.8	27
45	HPV induced triple neoplasms: a case report. <i>American Journal of Obstetrics and Gynecology</i> , 201, e9-e12.	0.7	0
46	MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 99.e1-99.e7.	0.7	40
47	RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. <i>International Journal of Oncology</i> , 2008, 32, 481-90.	1.4	29
48	Tumor-Associated Tn-MUC1 Glycoform Is Internalized through the Macrophage Galactose-Type C-Type Lectin and Delivered to the HLA Class I and II Compartments in Dendritic Cells. <i>Cancer Research</i> , 2007, 67, 8358-8367.	0.4	122
49	A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs. <i>Journal of Immunotherapy</i> , 2007, 30, 567-576.	1.2	26
50	Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors. <i>European Journal of Cancer</i> , 2007, 43, 2621-2627.	1.3	28
51	Regulated expression of MUC1 epithelial antigen in erythropoiesis. <i>British Journal of Haematology</i> , 2003, 120, 344-352.	1.2	19